6.27
전일 마감가:
$6.05
열려 있는:
$6.16
하루 거래량:
139.54K
Relative Volume:
0.13
시가총액:
$65.01M
수익:
-
순이익/손실:
$-6.42M
주가수익비율:
-1.1194
EPS:
-5.6013
순현금흐름:
$-7.45M
1주 성능:
-3.83%
1개월 성능:
-13.16%
6개월 성능:
+162.34%
1년 성능:
-63.38%
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
CRVO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CRVO
Cervomed Inc
|
6.27 | 65.01M | 0 | -6.42M | -7.45M | -5.6013 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
444.46 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.19 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.40 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
543.65 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
240.63 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
2024-12-06 | 개시 | ROTH MKM | Buy |
2024-12-05 | 개시 | H.C. Wainwright | Buy |
2024-09-18 | 개시 | Chardan Capital Markets | Buy |
2024-07-26 | 개시 | Morgan Stanley | Overweight |
2024-02-15 | 개시 | Canaccord Genuity | Buy |
2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
CervoMed’s (CRVO) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Pric - GuruFocus
CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Price Held Steady | CRVO Stock News - GuruFocus
CervoMed (CRVO) Strengthens Leadership with Key Executive Appoin - GuruFocus
CervoMed (CRVO) Strengthens Leadership with Key Executive Appointment | CRVO Stock News - GuruFocus
CervoMed appoints Marco Verwijs as EVP, technical operations - TipRanks
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - GlobeNewswire
CervoMed Accelerates Phase 3 DLB Drug Development With Key Manufacturing Expert Hire - Stock Titan
CRVOCervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - mx.advfn.com
Nuveen Asset Management LLC Acquires 22,104 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World
BNP Paribas Financial Markets Purchases New Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Reviewing CervoMed (CRVO) and Its Peers - Defense World
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
CervoMed Releases New Business and Financial Information - TipRanks
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
Chardan Capital Raises Earnings Estimates for CervoMed - Defense World
Roth Capital Brokers Reduce Earnings Estimates for CervoMed - Defense World
Brokers Set Expectations for CervoMed Q2 Earnings - Defense World
Insider Buying: William Elder Acquires Additional Shares of Cerv - GuruFocus
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from D. Boral Capital - Defense World
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates - MSN
CervoMed’s CFO Makes Bold Move with New Stock Purchase! - TipRanks
CervoMed First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Chardan keeps CervoMed stock Buy rating, $15 target post-results - Investing.com Australia
CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | - GuruFocus
Chardan Adjusts Price Target on CervoMed to $15 From $14, Maintains Buy Rating - marketscreener.com
CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | CRVO Stock News - GuruFocus
CervoMed Announces $50M Sales Agreement with Leerink - TipRanks
Chardan Capital Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World
CervoMed Inc. Reports Q1 2025 Financial Results - TipRanks
Chardan keeps CervoMed stock Buy rating, $15 target post-results By Investing.com - Investing.com South Africa
CervoMed Inc (CRVO) Q1 2025 Earnings: Revenue Beats Estimates at $1.9M, Net Loss Reported - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target | CRVO Stoc - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target | CRVO Stock News - GuruFocus
Cervomed Co Enters Sales Agreement With Leerink Partners LLC - marketscreener.com
CervoMed (CRVO) Financial Position and Funding Outlook | CRVO St - GuruFocus
CervoMed (CRVO) Exceeds Q1 Revenue Expectations Amid Promising T - GuruFocus
CervoMed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
SEC Form 10-Q filed by CervoMed Inc. - Quantisnow
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
CervoMed Inc. Reports Positive Phase 2b Results for Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies and Plans Phase 3 Trial - Nasdaq
CervoMed (CRVO) Financial Position and Funding Outlook | CRVO Stock News - GuruFocus
CervoMed (CRVO) to Release Earnings on Tuesday - Defense World
CervoMed Announces Executive Appointments and Changes - MSN
Mariner LLC Invests $30,000 in CervoMed Inc. (NASDAQ:CRVO) - Defense World
JPMorgan Chase & Co. Grows Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire
CRVO Shares Experience Surge in Value - knoxdaily.com
Head to Head Comparison: CervoMed (NASDAQ:CRVO) versus Schrödinger (NASDAQ:SDGR) - Defense World
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cervomed Inc 주식 (CRVO) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
ELDER WILLIAM ROBERT | CFO & GC |
Aug 27 '24 |
Buy |
18.16 |
1,000 |
18,160 |
1,267 |
자본화:
|
볼륨(24시간):